Drug Search Results
More Filters [+]

Axelopran

Alternative Names: axelopran, td-1211, td1211, td 1211
Latest Update: 2021-05-25
Latest Update Note: Clinical Trial Update

Product Description

A Peripherally Restricted mu-Opioid Receptor Antagonist (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31857840/)

Mechanisms of Action: OPR Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Theravance Biopharma
Company Location: GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Company CEO: Rick E Winningham
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Axelopran

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Constipation

Phase 1: Constipation|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ACTRN12614001152617

P1

Completed

Constipation

2014-10-20

NCT01702194

P1

Completed

Constipation

2013-02-01

22%

NCT01655771

P1

Completed

Constipation

2013-02-01

22%

NCT01568411

P1

Completed

Healthy Volunteers

2012-06-01

28%

Recent News Events

Date

Type

Title